BeiGene to Rebrand as BeOne Medicines With Oncology-Focused New Nasdaq Ticker "ONC"
BeiGene to Rebrand as BeOne Medicines With Oncology-Focused New Nasdaq Ticker "ONC"
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company that intends to change its name to BeOne Medicines Ltd., announced it will change its Nasdaq ticker symbol to "ONC" on January 2, 2025, reflecting its long-standing commitment to delivering innovative oncology medicines globally.
百济神州有限公司（纳斯达克：BGNE，香港交易所：06160，上海证券交易所：688235），一家全球肿瘤学公司，计划将其名称更改为BeOne Medicines Ltd.，并宣布将于2025年1月2日更改其纳斯达克标的为"ONC"，这反映了其长期致力于全球提供创新肿瘤药物的承诺。
"As we enter our 15th year, changing our ticker to ONC reflects our unwavering commitment to leadership in oncology and mission to deliver transformative medicines to cancer patients worldwide," said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. "This milestone inspires pride in all we have accomplished and fuels our excitement for the future as we advance our innovative hematology franchise and solid tumor pipeline, driving meaningful impact for patients everywhere."
百济神州联合创始人、董事长兼首席执行官约翰·沃伊勒说："在我们踏入第15个年头之际，将我们的标的更改为ONC反映了我们在肿瘤学领域的坚定领导承诺，以及向全球癌症患者提供变革性药物的使命。" "这一里程碑让我们为所取得的成就感到骄傲，并激发我们对未来的期待，推动我们推进创新的血液学事业和实体肿瘤管道，为每一位患者带来实质性影响。"
The Company's CUSIP number will remain unchanged. In addition, the Company stock codes and stock names for The Stock Exchange of Hong Kong and the STAR Market of the Shanghai Stock Exchange will not change. No action by the Company's shareholders is required to implement the Nasdaq ticker symbol change.
公司的CUSIP号码将保持不变。此外，公司在香港交易所和上海证券交易所科创板的股票代码和股票名称也将保持不变。公司的股东不需要采取任何行动来实施纳斯达克标的变更。
